Tamtam Try Tamtam free
Penumbra, Inc. logo

Penumbra, Inc. account plan

Medical device innovation company

At a glance

Penumbra makes thrombectomy, embolization and access devices to treat blood clots; $1,403.7 million revenue in FY2025, sale to Boston Scientific pending.

Penumbra, Inc. (Alameda, California; NYSE: PEN), founded in 2004, develops, manufactures and sells devices that remove blood clots from head to toe (pulmonary embolism, deep vein thrombosis, acute limb ischemia, ischemic stroke), plus embolization coils and neurovascular access catheters. Hospitals buy, guided by specialist physicians such as interventional radiologists, neuroradiologists and vascular surgeons; about 90% of revenue is direct sales and the United States is 77.8% of revenue. FY2025 revenue was $1,403.7 million, up 17.5%, with income from operations of $189.2 million and net income of $177.7 million. Penumbra had about 4,700 employees at December 31, 2025 and makes substantially all products in Alameda and Roseville, California. Boston Scientific agreed on January 14, 2026 to acquire it at $374 per share, with closing now expected in early 2027.

Business units

Strategic priorities

CAVT across the body
Extend computer assisted vacuum thrombectomy through new Lightning Flash and Lightning Bolt generations in venous, pulmonary and arterial clot and bring it to stroke with THUNDERBOLT; Penumbra cites over 800,000 U.S. patients with VTE and arterial clot.
Change pulmonary embolism protocols
Use the STORM-PE trial, which showed CAVT superior to anticoagulation alone in intermediate-high-risk PE, to get hospitals, pulmonologists and hematologists to update PE protocols, one of the top priorities named for the next year.
Embolization as an equal growth driver
Grow embolization through the new 50-plus rep peripheral sales team, the Ruby XL launch and Swift coils in middle meningeal artery embolization.
Gross margin expansion
Management targeted a gross margin profile of over 70% by 2026; gross margin was 68.3% in Q3 2026.
Close the Boston Scientific merger
Complete the $374 per share sale, approved by stockholders, with closing expected in early 2027; Penumbra is to run as a standalone organization within Boston Scientific's cardiovascular group.

Latest results

In Q3 2026 (quarter ended September 30, 2026) revenue rose 15.6% to $410.1 million from $354.7 million, with Thrombectomy up 18.1% and Embolization and Access up 10.8%; international revenue rose 7.8% to $85.9 million. Gross margin improved to 68.3% from 67.8% on favorable product mix. SG&A rose 20.9% to $204.2 million, including $7.1 million of acquisition-related expenses, so income from operations was $50.7 million against $48.8 million. Over nine months revenue was $1,174.9 million (+15.4%) and income from operations flat at $130.0 million. Penumbra gives no numeric guidance while the merger is pending.

Investments and deals

Costa Rica manufacturing plant
A manufacturing facility and warehouse of approximately 330,000 square feet, now expected to cost approximately $91 million after an increase of approximately $31 million; $57.6 million had been paid by September 30, 2026.
Sale to Boston Scientific
Agreed January 14, 2026 at $374 per share, an enterprise value of approximately $14.5 billion, about 73% cash and 27% stock; termination fees are $525.0 million (Penumbra) and $900.0 million (Boston Scientific).
Peripheral embolization sales team
Over 50 dedicated peripheral embolization reps added in 2025 so the existing peripheral team could focus only on CAVT.
Immersive healthcare exit
The virtual reality business was wound down in 2024 at a cost of $115.3 million in impairment and other charges.

Challenges and risks

Merger uncertainty
The pending deal creates uncertainty for employees, customers and suppliers, adds transaction costs ($23.5 million of acquisition-related expenses over nine months of 2026) and has slipped from end-2026 to early 2027.
Intense competition
Boston Scientific, Medtronic, Stryker (now including Inari Medical) and Terumo compete, most with greater resources and the ability to bundle products.
Rising SG&A holds back profit
SG&A rose 23.5% over nine months of 2026 on headcount, deal costs and marketing events, keeping income from operations flat despite 15.4% revenue growth.
Product concentration and regulatory timing
Most revenue comes from a limited number of product families, and new products depend on FDA clearances; THUNDERBOLT spent a long period in 510(k) review.
Hospital cost containment
Hospitals are reimbursed at fixed MS-DRG rates regardless of device, and new products need value analysis committee approval, so cost-effectiveness drives adoption.

What leadership says

“We remain on track and are well-positioned to achieve a gross margin profile of over 70% by 2026”

Adam Elsesser, Chairman and CEO · Q3 2025 earnings call, November 5, 2025

“We are entering a very clear next phase of this company where the product innovation has progressed to the point where we really just have the most extraordinary best-in-class products across the whole portfolio.”

Adam Elsesser, Chairman and CEO · Boston Scientific / Penumbra acquisition conference call, January 15, 2026

“So neuro is really set up for some significant growth”

Adam Elsesser, Chairman and CEO · Boston Scientific / Penumbra acquisition conference call, January 15, 2026

“there was nothing one time about this quarter”

Adam Elsesser, Chairman and CEO · Q3 2025 earnings call, November 5, 2025, on embolization growth

Where a supplier can help

Costa Rica plant build-out
The approximately $91 million Costa Rica facility, whose cost rose on evolving design requirements, needs construction, cleanroom, equipment and supply-chain partners.
Clinical evidence and protocol adoption
Turning STORM-PE into updated hospital PE protocols calls for medical education, real-world evidence and hospital outreach services aimed at pulmonologists and hematologists.
Sales force productivity
Penumbra's growth depends on adding salespeople and how fast they become effective, and SG&A is rising faster than revenue: sales training, CRM and field analytics vendors fit this need.
Integration readiness
The Boston Scientific deal, with synergies sought in G&A, operations and international go-to-market, opens work for integration, IT and finance consultants before and after closing.
Manufacturing margin
The target of a gross margin over 70% points to suppliers of automation, quality and component cost reduction for the Alameda and Roseville plants.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Penumbra, Inc.?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Penumbra, Inc.

What does Penumbra do?

Penumbra develops, manufactures and sells medical devices that remove blood clots from head to toe, including CAVT thrombectomy systems, plus embolization coils and neurovascular access catheters.

What is Penumbra's revenue?

FY2025 revenue was $1,403.7 million, up 17.5%. Q3 2026 revenue was $410.1 million, up 15.6%.

How many employees does Penumbra have?

Penumbra had about 4,700 employees at December 31, 2025.

Who is acquiring Penumbra?

Boston Scientific agreed on January 14, 2026 to acquire Penumbra at $374 per share, an enterprise value of approximately $14.5 billion; stockholders approved it and closing is expected in early 2027.

Who leads Penumbra?

Founder Adam Elsesser is Chairman and CEO; Maggie Yuen is Chief Financial Officer.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)